


WE CLAIM:

1 1. A formulation for oral administration of relacorilant, (R)-(1-(4-
2 fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-
3 g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, which has the following
4 structure:



6 the formulation comprising:

7 about 18% to 22% relacorilant;

8 about 55% to 65% surfactant,

9 where said surfactant is selected from sorbitan surfactants, polysorbate
10 surfactants, polyoxyl glyceride surfactants, ionic surfactants, and non-ionic surfactants;

11 and

12 about 18% to 22% solubilizer,

13 where said solubilizer is selected from polyethylene glycols, propylene glycol
14 esters, ethanol, propylene glycol, glycerols, glycerin, *N*-methyl-2-pyrrolidone,
15 dimethylacetamide, and dimethylsulfoxide, wherein said percentages are weight percent.

1 2. The formulation of claim 1, further including an antioxidant.

1 3. The formulation of claim 2, wherein the formulation comprises about
2 0.02% antioxidant.

1 4. The formulation of claim 2, wherein the surfactant is a lauroyl polyoxy
2 glyceride.

- 1 5. The formulation of claim 2, consisting of 20% relacorilant, 59.98%
2 Lauroyl poloxyl-32 glycerides, 20% Propylene glycol monocaprylate, and 0.02% Butylated
3 hydroxytoluene (BHT).
- 1 6. The formulation of claim 5, consisting of 25 mg relacorilant, 74.975 mg
2 Lauroyl poloxyl-32 glycerides, 25 mg Propylene glycol monocaprylate, and 0.025 mg Butylated
3 hydroxytoluene (BHT).
- 1 7. The formulation of claim 5, consisting of 50 mg relacorilant, 149.95 mg
2 Lauroyl poloxyl-32 glycerides, 50 mg Propylene glycol monocaprylate, and 0.05 mg Butylated
3 hydroxytoluene (BHT).
- 1 8. The formulation of claim 5, consisting of 100 mg relacorilant, 299.9 mg
2 Lauroyl poloxyl-32 glycerides, 100 mg Propylene glycol monocaprylate, and 0.1 mg Butylated
3 hydroxytoluene (BHT).
- 1 9. The formulation of claim 5, consisting of 200 mg relacorilant, 599.8 mg
2 Lauroyl poloxyl-32 glycerides, 200 mg Propylene glycol monocaprylate, and 0.2 mg Butylated
3 hydroxytoluene (BHT).
- 1 10. The formulation of claim 5, consisting of 300 mg relacorilant, 899.7 mg
2 Lauroyl poloxyl-32 glycerides, 300 mg Propylene glycol monocaprylate, and 0.3 mg Butylated
3 hydroxytoluene (BHT).
- 1 11. The formulation of claim 5, consisting of 400 mg relacorilant, 1199.6 mg
2 Lauroyl poloxyl-32 glycerides, 400 mg Propylene glycol monocaprylate, and 0.4 mg Butylated
3 hydroxytoluene (BHT).
- 1 12. The formulation of claim 5, consisting of 500 mg relacorilant, 1499.5 mg
2 Lauroyl poloxyl-32 glycerides, 500 mg Propylene glycol monocaprylate, and 0.5 mg Butylated
3 hydroxytoluene (BHT).
- 1 13. The formulation of claim 5, consisting of 750 mg relacorilant, 2249.25 mg
2 Lauroyl poloxyl-32 glycerides, 750 mg Propylene glycol monocaprylate, and 0.75 mg Butylated
3 hydroxytoluene (BHT).
- 1 14. A unit dose for oral administration of relacorilant, consisting essentially of
2 a softgel capsule containing a relacorilant formulation consisting of 20% relacorilant, 59.98%

3 Lauroyl poloxyl-32 glycerides, 20% Propylene glycol monocaprylate, and 0.02% Butylated
4 hydroxytoluene (BHT), wherein said percentages are weight percentages.

1 15. The unit dose for oral administration of relacorilant of claim 14, said
2 softgel capsule containing a relacorilant formulation consisting of 25 mg relacorilant, 74.975 mg
3 Lauroyl poloxyl-32 glycerides, 25 mg Propylene glycol monocaprylate, and 0.025 mg Butylated
4 hydroxytoluene (BHT).

1 16. The unit dose for oral administration of relacorilant of claim 14, said
2 softgel capsule containing a relacorilant formulation consisting of 50 mg relacorilant, 149.95 mg
3 Lauroyl poloxyl-32 glycerides, 50 mg Propylene glycol monocaprylate, and 0.05 mg Butylated
4 hydroxytoluene (BHT).

1 17. The unit dose for oral administration of relacorilant of claim 14, said
2 softgel capsule containing a relacorilant formulation consisting of 100 mg relacorilant, 299.9 mg
3 Gelucire Lauroyl poloxyl-32 glycerides, 100 mg Propylene glycol monocaprylate, and 0.1 mg
4 Butylated hydroxytoluene (BHT).

1 18. The unit dose for oral administration of relacorilant of claim 14, said
2 softgel capsule containing a relacorilant formulation consisting of 200 mg relacorilant, 599.8 mg
3 Lauroyl poloxyl-32 glycerides, 200 mg Propylene glycol monocaprylate, and 0.2 mg Butylated
4 hydroxytoluene (BHT).

1 19. The unit dose for oral administration of relacorilant of claim 14, said
2 softgel capsule containing a relacorilant formulation consisting of 300 mg relacorilant, 899.7 mg
3 Lauroyl poloxyl-32 glycerides, 300 mg Propylene glycol monocaprylate, and 0.3 mg Butylated
4 hydroxytoluene (BHT).

1 20. The unit dose for oral administration of relacorilant of claim 14, said
2 softgel capsule containing a relacorilant formulation consisting of 400 mg relacorilant, 1199.6
3 mg Lauroyl poloxyl-32 glycerides, 400 mg Propylene glycol monocaprylate, and 0.4 mg
4 Butylated hydroxytoluene (BHT).

1 21. The unit dose for oral administration of relacorilant of claim 14, said
2 softgel capsule containing a relacorilant formulation consisting of 500 mg relacorilant, 1499.5

3 mg Lauroyl poloxyl-32 glycerides, 500 mg Propylene glycol monocaprylate, and 0.5 mg
4 Butylated hydroxytoluene (BHT).

1 22. The unit dose for oral administration of relacorilant of claim 14, said
2 softgel capsule containing a relacorilant formulation consisting of 2249.25 mg Lauroyl poloxyl-
3 32 glycerides, 750 mg Propylene glycol monocaprylate, and 0.75 mg Butylated hydroxytoluene
4 (BHT).

1

1

1

1

1

1

1

1

1